dacarbazine

Notably, COS-2 not only enhanced the anti-tumor efficacy of DTIC but also alleviated its side effects. The combination therapy with COS and DTIC exhibited a synergistic effect and may be a promising therapeutic strategy for melanoma.

Interestingly, some of these patients may derive meaningful benefit from cytotoxic chemotherapy. We present the report of a case of a 63-year-old lady with BRAF wild type, locally advanced mucosal melanoma who demonstrated disease progression on combination immunotherapy with Ipilimumab and nivolumab. She subsequently achieved an exceptional and durable radiological and clinical response to chemotherapy with cisplatin and dacarbazine. This case highlights that, despite advances in personalized medicine and immunotherapy, conventional chemotherapy may still represent a valuable therapeutic option in selected patients, particularly in the refractory setting.

P3, N=2921, Completed, University of Giessen | Active, not recruiting --> Completed | N=2200 --> 2921 | Trial completion date: Sep 2026 --> Oct 2025

After receiving six cycles of brentuximab+doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy at our Department of Hematology (University of Debrecen), the patient achieved complete metabolic remission (CMR) and remains in good condition. HL-RT in CLL is relatively rare and generally associated with poorer outcomes, though it is typically more favorable than DLBCL-RT. In this case report, we highlight not only an uncommon anatomical location of HL-RT but also the absence of typical predisposing factors, such as a TP53 mutation, unmutated immunoglobulin heavy chain (IGHV) status, or a lack of 13q deletion.

P2, N=378, Completed, Immunocore Ltd | Active, not recruiting --> Completed

P2, N=92, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting

P3, N=1334, Completed, Takeda | Active, not recruiting --> Completed

P3, N=78, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting | N=470 --> 78

P3, N=325, Recruiting, Advenchen Laboratories, LLC | Active, not recruiting --> Recruiting | Trial completion date: Jun 2025 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2027

P4, N=124, Recruiting, Takeda | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028

P2, N=340, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2027 --> Nov 2026 | Trial primary completion date: Feb 2027 --> Nov 2026

P1/2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027